ArticleNPJ precision oncology2026
HAMNO and CGK733 as BRCAness-driven candidates exhibit synthetic lethality with olaparib in BRCA-proficient ovarian cancer.
Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Olaparib has low efficacy against BRCA-proficient ovarian cancer (OC); improving the efficacy of olaparib is expected to improve the prognosis of OC. In clinical practice, some BRCA-proficient cancers, similar to tumors with BRCA mutations, are sensitive to poly ADP‒ribose polymerase inhibitors (PARPis), a phenomenon known as BRCAness. This study aimed to identify BRCAness-inducing inhibitors that enhance olaparib antitumor efficacy in BRCA-proficient OC using patient-derived organoids (PDOs). We screened 28 inhibitors and evaluated their therapeutic value in combination with olaparib. Ultimately, an RPA70 inhibitor (HAMNO) and an ATR inhibitor (CGK733) significantly increased olaparib toxicity without causing major organ damage in mice. Mechanistically, HAMNO inhibits RPA70 binding to single-strand DNA (ssDNA) and hinders the recruitment of RAD51 at DNA double-strand breaks (DSBs), impairing homologous recombination repair (HRR). CGK733 induced BRCAness by blocking ATR function. Furthermore, the combination therapy with Olaparib was highly effective at inducing G2 phase arrest and inhibiting HRR. In addition, high RPA70 and ATR expression was found to indicate a poor prognosis in OC patients according to data from the Kaplan-Meier plotter database and clinical data from our center. In conclusion, our work provides an innovative approach for improving the therapeutic effect of olaparib on BRCA-proficient OC.
Identifiers
42850290What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.